A hearing will get underway in Delaware later today in the latest phase of GSK’s attempts to defend itself from allegations that its Zantac drug caused cancer in patients. The three-day hearing ...

Shares in GSK fell around 9% this morning after a judge in a Delaware court gave the green light for tens of thousands of lawsuits claiming harm by gastrointestinal drug Zantac to proceed to trial.

The placebo was composed of hydrogenated glucose syrup, xanthane gum, methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), erythrosine (E217), fennel flavour, titanium oxide ...

His oral medications prior to admission included topiramate 100 mg twice daily, ranitidine hydrochloride 75 mg twice daily, ferrous sulfate 325 mg twice daily, potassium chloride 10 meq once daily ...